Evofem Presents Data Detailing Fewer Urinary Tract Infections in Women Using Phexxi in the Phase 3 AMPOWER Clinical Trial

5.8% of Women in the AMPOWER Trial Experienced an On-Study Urinary Tract Infection Compared to 11% in the General Population The Post hoc Analysis will be Presented at the 2022 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting in San Diego, CA on May 7, 2022 SAN…

Click here to view original post